Revenue
$3.22B
Gross Margin
+36.2%
Operating Margin
+20.7%
Net Margin
+16.9%
Income statement waterfall for West Pharmaceutical Services (WST) — TTM through Q1 2026
Net income: $542.70M
Margin breakdown for West Pharmaceutical Services (WST) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Revenue | $3.22B | $3.22B |
| Cost of Revenue | −$2.05B | $1.17B |
| Gross Profit | $1.17B | $1.17B |
| Operating Expenses | −$501.40M | $665.60M |
| Operating Income | $665.60M | $665.60M |
| Other Income / Expense | $15.90M | $681.50M |
| Pre-tax Income | $681.50M | $681.50M |
| Income Tax | −$142.20M | $539.30M |
| Net Income | $542.70M | $542.70M |
- Revenue$3.22B
- Cost of Revenue−$2.05B
- Gross Profit$1.17B
- Operating Expenses−$501.40M
- Operating Income$665.60M
- Other Income / Expense$15.90M
- Pre-tax Income$681.50M
- Income Tax−$142.20M
- Net Income$542.70M
Want to see what changed vs last year?Profit Bridge
Frequently asked questions
Data & methodology
West Pharmaceutical Services (WST) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement